- Q1 2024 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024€201.3 (-7.53%)Earnings
- Madrigal Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Madrigal Pharmaceuticals Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call TranscriptJun 24, 2023
- Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Madrigal Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptMay 16, 2023
- Madrigal Pharmaceuticals Inc to Announce Topline Data from the Phase 3 MAESTRO-NASH Study of Resmetirom Presentation TranscriptDec 19, 2022
- Madrigal Pharmaceuticals Inc EASL Investor Event Call TranscriptJun 25, 2022
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 24, 2022
- Q1 2022 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2022€54.5 (-10.66%)Earnings
- Madrigal Pharmaceuticals Inc Call to Discuss MAESTRO-NAFLD-1 Phase 3 Data TranscriptJan 31, 2022
- Madrigal Pharmaceuticals Inc AASLD The Liver Meeting Call TranscriptNov 16, 2021
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 19, 2020
Madrigal Pharmaceuticals Inc EASL Investor Event Call Transcript
So thank you all for coming. And for those who have joined on the webcast, welcome. With me today, I have Dr. Becky Taub, President of R&D and Chief Medical Officer of Madrigal; and Stephen Harrison needs no introduction, lead investigator of our Phase III MAESTRO studies, resmetirom.
Please see today's press release, unless you want to memorize this for our forward-looking statements and I ask you to look at the press release today and our SEC filings for forward-looking statements and risk factor considerations associated with these statements and our business. The EASL 2022 International Liver Congress has been a busy time for Madrigal. Earlier today, we presented late-breaking data from our Phase III MAESTRO-NAFLD-1 safety study of resmetirom. This was the first presentation of the double-blind results in a major scientific meeting and we're going to review some of that data shortly. We and our collaborators presented 3 additional oral abstracts and 2 posters among the oral abstracts or analyses of new data from the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)